Merck announced the first results from the Phase 3 CORALreef HeFH trial, showing that its investigational drug enlicitide decanoate, a once-daily oral PCSK9 inhibitor, reduced LDL-C by 59.4% compared to placebo in adults with heterozygous familial hypercholesterolemia (HeFH) after 24 weeks. https://www.coherentmarketinsights.com/news/samsung-heavy-industries-collaborated-with-dsec-1842